Form 4: Viking Therapeutics Director Acquires 18,800 Stock Options

Viking Therapeutics director Matthew W. Foehr acquired 18,800 stock options on January 2, 2025.

Summary

• Matthew W. Foehr, a director at Viking Therapeutics, acquired 18,800 stock options on January 2, 2025.
• These options have an exercise price of $41.12.
• The options become exercisable on January 2, 2026, and expire on January 2, 2035.
• The underlying security for these options is 18,800 shares of Viking Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director's alignment with the company's success. It is not a major event, but it is a positive indicator.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The terms of these options, such as the exercise price, vesting period, and expiration date, are typical for such grants.
• Similar filings can be seen across the biotechnology industry, for example, in companies like Madrigal Pharmaceuticals or Intercept Pharmaceuticals, where directors and officers regularly report their transactions.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, Viking Therapeutics, director, equity, Matthew W. Foehr